Target intelligence / Profile preview

Nucleotide-binding oligomerization domain-containing protein 2 (NOD2) (NOD2)

Target
NOD2
Molecular classification
Pattern recognition receptor, NOD-like receptor, Intracellular receptor, NLR family
01

Overview

Nucleotide-binding oligomerization domain-containing protein 2 (NOD2) is a cytosolic pattern recognition receptor that serves as a primary sensor for bacterial peptidoglycan fragments, specifically muramyl dipeptide (MDP). Upon ligand binding, NOD2 undergoes a conformational change and oligomerization, recruiting the kinase RIPK2 to activate the NF-kappaB and MAP kinase pathways, which are essential for the innate immune response and the production of antimicrobial peptides. Genetic variations in NOD2 are highly significant in clinical medicine; loss-of-function mutations are strongly linked to an increased risk of Crohn's disease due to impaired mucosal immunity, while gain-of-function mutations cause Blau syndrome, a systemic granulomatous disorder. In the context of drug development, NOD2 is targeted by agonists like mifamurtide to enhance immune responses in oncology, and by small-molecule inhibitors designed to treat chronic inflammatory conditions. Beyond its role in inflammation, NOD2 also regulates autophagy and maintains the integrity of the intestinal barrier, making it a central regulator of host-microbe interactions. The protein's structure, featuring N-terminal CARD domains, a central NOD domain, and C-terminal leucine-rich repeats, provides multiple sites for therapeutic intervention and allosteric modulation.

Other names
Caspase recruitment domain-containing protein 15CARD15Inflammatory bowel disease protein 1IBD1NOD2BBlau syndrome proteinArthrocutaneouveal granulomatosis protein
02

Mechanism of action

NOD2 agonists bind to the C-terminal leucine-rich repeat domain, triggering a conformational change that allows the nucleotide-binding domain to oligomerize and the N-terminal CARD domains to recruit RIPK2, ultimately activating NF-kB and MAPK pathways to induce pro-inflammatory gene expression. Inhibitors target these protein-protein interactions or the ATP-binding site to dampen excessive inflammatory signaling.

03

Biological functions

Immune responseSignal transductionApoptosisAutophagyInflammatory responseBacterial peptidoglycan recognition
04

Disease associations

Crohn's diseaseBlau syndromeSarcoidosisGraft-versus-host diseaseInfectionOsteosarcoma
05

Safety considerations

Potential for cytokine release syndromeRisk of granulomatous disease exacerbationImpaired clearance of intracellular pathogensIntestinal dysbiosisSystemic inflammatory response
06

Interacting drugs

4 more in the full profile.

07

Biomarkers

NOD2 gene mutations (e.g., R702W, G908R, 1007fs)RIPK2 phosphorylation statusNF-kB nuclear translocationMuramyl dipeptide levels

Beyond the preview

Go deeper on Nucleotide-binding oligomerization domain-containing protein 2 (NOD2) (NOD2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nucleotide-binding oligomerization domain-containing protein 2 (NOD2) (NOD2).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call